Aquestive Q2 revenue up 38% to $13.8M; Anaphylm NDA resubmission on track for Q3 2026

Aquestive Therapeutics, Inc.

Q2 revenue $13.8M vs $10.0M; manufacture/supply $11.9M, license/royalty $1.3M.
Net loss $22.9M ($0.18/sh) includes $11.7M one-time debt extinguishment; ex-item net loss $11.2M.
Non-GAAP adjusted EBITDA loss improved to $5.2M from $9.3M; cash $98.5M at June 30.
Anaphylm PK study met primary endpoints; human factors study improved; NDA resubmission on track for Q3 2026.
FY2026 guidance unchanged: revenue $46-50M, adj. EBITDA loss $35-30M; manufacturing 48M doses vs 37M.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.